We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 03, 2020

Efficacy and Safety of Anti–PD-1 Immunotherapy for Advanced NSCLC With BRAF, HER2, or MET Mutation or RET-Translocation

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced Non Small Cell Lung Cancer With BRAF, HER2 or MET Mutation or RET-Translocation. GFPC 01-2018
J Thorac Oncol 2020 Jan 13;[EPub Ahead of Print], F Guisier, C Dubos-Arvis, F Viñas, H Doubre, C Ricordel, S Ropert, H Janicot, M Bernardi, P Fournel, R Lamy, M Pérol, J Dauba, G Gonzales, L Falchero, C Decroisette, P Assouline, C Chouaid, O Bylicki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading